Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000244170 | SCV000305751 | benign | not specified | criteria provided, single submitter | clinical testing | ||
ARUP Laboratories, |
RCV001001711 | SCV001159292 | benign | Polycystic kidney disease, adult type | 2018-10-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000244170 | SCV001476739 | benign | not specified | 2020-02-07 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001292302 | SCV001480581 | likely benign | Polycystic kidney disease | no assertion criteria provided | clinical testing | The PKD1 p.His1769= variant was identified in 2 of 550 proband chromosomes (frequency: 0.003636) from individuals or families with autosomal dominant polycystic kidney disease (ADPKD) (Rossetti 2002, Rossetti 2012). The variant was also identified in dbSNP (ID: rs575064371) “With Benign allele,” ClinVar (as benign by Prevention Genetics), and ADPKD Mutation Database (2x as likely neutral). The variant was not identified in GeneInsight-COGR, LOVD 3.0, and PKD1-LOVD databases. The variant was identified in control databases in 105 of 275770 chromosomes at a frequency of 0.0004 increasing the likelihood that this may be a low frequency benign variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017), being identified in the following populations: African in 98 of 23838 chromosomes (frequency: 0.004), Ashkenazi Jewish in 1of 10092 chromosomes (frequency: 0.0001), Latino in 3 of 34408 chromosomes (frequency: 0.00009), East Asian in 1 of 18858 chromosomes (frequency: 0.00005), and European Non-Finnish in 2 of 125618 chromosomes (frequency: 0.00002). In addition we cannot be certain that data from control databases is specific to PKD1 and not from one of the six PKD1 pseudogenes. The p.His1769= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |